Where would you like to sign in?

BREAKTHROUGH FINDING LINKS AGEING WITH STEM CELL EXHAUSTION

LEIDEN, NETHERLANDS--(Marketwire - June 7, 2007) -

Leiden, The Netherlands, June 7, 2007. Biotech company Pharming
Group
NV ("Pharming" or "the Company") (Euronext: PHARM) today
announced
that the founders of its subsidiary DNage have published new
insights
in the field of aging in the leading scientific journal Nature.

Findings

Professor Irving Weissman and his team at Stanford University
(CA,
USA) together with DNage's scientific founder professor
Jan
Hoeijmakers of the Erasmus Medical Center (Rotterdam, NL) have
shown,
using of one DNage's mouse models, that accumulation of DNA
damage
progressively limits functional capacity of stem cells. This
finding
is very important in a number of ways: firstly, it strengthens
the
link between DNA damage and ageing. Secondly, it establishes a
clear
model on how the accumulation of DNA damage leads to ageing
of
tissues and organs. Thirdly, these data further support
the
suitability of our proprietary mouse models in ageing and stem
cell
research. Finally, the findings provide Pharming with clear angles
on
how to approach the treatment or prevention of ageing diseases.
This
insight is currently being applied to develop novel approaches
for
treatment of osteoporosis and neurodegeneration.

Background on the principal authors

Jan Hoeijmakers, PhD is the head of the department of Genetics at
the
Erasmus Medical Center in Rotterdam. His work focuses for the
past
twenty-five years on DNA damage and repair. He and his team were
the
first to clone a DNA repair gene in the early 80's, have generated
an
extensive collection of mouse models and were also the first
that
established the link between DNA damage accumulation and ageing.
In
2004 Jan Hoeijmakers co-founded DNage based on these findings.
Irving
Weissman, PhD, is the Director of the Stanford Institute of Stem
Cell
Biology and Regenerative Medicine at Stanford University, Palo
Alto,
California, US. Prof Weissman is one of the leading experts
worldwide
in the field of stemcell biology. He has been active in this
field
for more than 30 years and is considered to be one of the founders
of
the field of adult stem cell biology. Dr. Weissman is also
the
founder of several companies including Systemix, a successful
biotech
company in the field of stemcells which was sold to Novartis in
the
90's.

Background on Pharming Group NV

Pharming Group NV is developing innovative products for the
treatment
of genetic disorders, ageing diseases, specialty products
for
surgical indications, intermediates for various applications
and
nutritional products. Pharming has two products in late
stage
development - Rhucin® (recombinant human C1 inhibitor) for
hereditary
angioedema (MAA under review by EMEA) and human lactoferrin for
use
in food products (GRAS notification under review by US FDA).
The
advanced technologies of the Company include innovative platforms
for
the production of protein therapeutics and technology and
processes
for the purification and formulation of these products, as well
as
technologies in the field of tissue repair (via its
collaboration
with NovaThera) and DNA repair (via its subsidiary DNage).
Additional
information is available on the Pharming
website,
http://www.pharming.com and on http://www.dnage.nl.

This press release contains forward looking statements that
involve
known and unknown risks, uncertainties and other factors, which
may
cause the actual results, performance or achievements of the
Company
to be materially different from the results, performance
or
achievements expressed or implied by these forward
looking
statements. The press release also appears in Dutch. In the event
of
any inconsistency, the English version will prevail over the
Dutch
version.